Lipocine (NASDAQ:LPCN) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN) from a sell rating to a hold rating in a research note released on Sunday morning.

Several other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Lipocine has an average rating of “Moderate Buy” and an average target price of $15.00.

Lipocine Stock Performance

Shares of LPCN stock opened at $7.15 on Friday. The firm has a fifty day moving average of $9.06 and a 200-day moving average of $5.53. The stock has a market cap of $52.20 million, a price-to-earnings ratio of -4.24 and a beta of 0.98. Lipocine has a 52-week low of $2.52 and a 52-week high of $12.37.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.26. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Institutional Investors Weigh In On Lipocine

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Squadron Capital Management LLC acquired a new stake in shares of Lipocine in the fourth quarter valued at $4,256,000. Diadema Partners LP acquired a new position in Lipocine during the 4th quarter worth about $2,095,000. Ikarian Capital LLC bought a new stake in Lipocine during the 4th quarter worth about $1,602,000. Persistent Asset Partners Ltd acquired a new stake in Lipocine in the 4th quarter valued at about $567,000. Finally, Boothbay Fund Management LLC acquired a new stake in Lipocine in the 4th quarter valued at about $441,000. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.